secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001650664-25-000071
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas Q1 net loss $76.1M ($0.92/share); cash $221M runway into Q2 2027
-----------------------------------------------------------------------

- Net loss $76.1M ($0.92 per share) vs $62.0M loss in Q1 2024; revenue $4.7M (up from $1.1M).
- R&D expenses fell to $26.6M from $48.8M; restructuring charges $40.9M from reni-cel discontinuation.
- Cash, equivalents, and marketable securities $221.0M; expected to fund operations into Q2 2027.
- Amy Parison appointed CFO; previously SVP Finance and Corporate Controller at Editas since 2022.
- Federal Circuit vacated PTAB decision on CRISPR/Cas9 patents; remanded for further review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066425000071/0001650664-25-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066425000071/edit-20250512.htm
  HTML page:      https://secwatch.observer/filing/0001650664-25-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer